<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681651</url>
  </required_header>
  <id_info>
    <org_study_id>OPENS-2</org_study_id>
    <nct_id>NCT04681651</nct_id>
  </id_info>
  <brief_title>Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)</brief_title>
  <official_title>A Randomized Controlled Trial Assessing the Efficacy and Safety of Normobaric Hyperoxia for Acute Ischemic Stroke Patients Undergoing Endovascular Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Huanhu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengli Oilfield Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Fengtai You'anmen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiujiang University Affiliated Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current endovascular treatment has increased the recanalization rate to more than 90%.&#xD;
      Even so, the prognosis rate of stroke is still less than 50%. Our previous research confirmed&#xD;
      that the neuroprotective effect of Normobaric Hyperoxia (NBO) from multiple perspectives.&#xD;
      However, the clinical study on NBO was not satisfactory, which might be due to the absence of&#xD;
      vascular recanalization therapy. Therefore, The investigators conducted this RCT study to&#xD;
      further explore the Efficacy and safety of NBO combined with endovascular treatment in&#xD;
      patients with acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale（mRS） score</measure>
    <time_frame>90 ± 10 days after randomization</time_frame>
    <description>the mRs is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability,and 6=death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral infarct volume</measure>
    <time_frame>24-48h after randomization</time_frame>
    <description>The infarct volume of cerebral infarct is evaluated by MRI-DWI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of good prognosis</measure>
    <time_frame>90 ± 10 days after randomization</time_frame>
    <description>the mRs is an ordinal disability score of 7 categories (0 = no symptoms to 5 = severe disability, and 6 = death);The ratio of 0 to 2;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional independence</measure>
    <time_frame>90 ± 10 days after randomization</time_frame>
    <description>The Proportion of mRS 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of mRS 0-3</measure>
    <time_frame>90 ± 10 days after randomization</time_frame>
    <description>secondary clinical efficacy endpoint;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores assessed by National Institutes of Health Stroke Scale(NIHSS)</measure>
    <time_frame>4h, 24h, 72h, day7 after randomization</time_frame>
    <description>Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological function improvement rate</measure>
    <time_frame>24 ± 6 hours</time_frame>
    <description>NIHSS score increased by more than 4 points);the NIHSS is a stroke severity score composed of 11 items (range from 0 to 42, higher values indicate more severe deficits);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS score</measure>
    <time_frame>30 ± 7 days after randomization</time_frame>
    <description>the mRs is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability,and 6=death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (BI)</measure>
    <time_frame>30 ± 7 days, 90 ± 10 days after randomization;</time_frame>
    <description>the BI is an ordinal disability score of 10 categories(range from 0 to 100, higher values indicate better prognosis);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average days of hospitalization</measure>
    <time_frame>30 days</time_frame>
    <description>Length of stay in hospital;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intracranial contrast agent extravasation</measure>
    <time_frame>24 ± 12 hours</time_frame>
    <description>observed by dual-energy CT;We observed the proportion of contrast extravasation in the two groups. The higher the incidence, the more likely the blood-brain barrier was to be destroyed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment( MoCA)</measure>
    <time_frame>90 ± 10 days after randomization</time_frame>
    <description>Cognitive function score;The highest score was 30, and the higher the score, the worse the cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimensions questionnaire（EQ-5D）</measure>
    <time_frame>30 ± 7 days, 90 ± 10 days after randomization;</time_frame>
    <description>The score ranges from 0 to 100, with 100 indicating optimal health；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke-related mortality</measure>
    <time_frame>90 ± 10 days after randomization</time_frame>
    <description>clinical safety endpoint;The proportion of stroke related deaths in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptomatic intracranial hemorrhage</measure>
    <time_frame>24 (12 to 36) hours</time_frame>
    <description>Deterioration in NIHSS score of ≥4 points within 24 hours;To observe the proportion of symptomatic intracranial hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early neurological deterioration(END)</measure>
    <time_frame>7± 2 days after randomization</time_frame>
    <description>defined as NIHSS score increased by ≧4 points within 7 days);To observe the proportion of END in each group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality;</measure>
    <time_frame>90 ± 10 days after randomization</time_frame>
    <description>clinical safety endpoint; to observe the proportion of all patients who died in each group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse event</measure>
    <time_frame>24 ± 6 hours;7± 2 days after randomization</time_frame>
    <description>24h incidence of surgery-related complications: vascular perforation, arterial dissection, and distal embolization;Incidence of pneumonia within 7 days;Incidence of deep vein thrombosis within 7 days;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any intracranial hemorrhage</measure>
    <time_frame>24 (12 to 36) hours]</time_frame>
    <description>imaging safety endpoints; to observe the proportion of intracranial hemorrhage patients in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Neuroprotection</condition>
  <arm_group>
    <arm_group_label>NBO group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normobaric Hyperoxia combined with endovascular mechanical thrombectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhale air placebo plus endovascular mechanical thrombectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normobaric Hyperoxia</intervention_name>
    <description>Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.</description>
    <arm_group_label>NBO group</arm_group_label>
    <other_name>NBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham Normobaric Hyperoxia</intervention_name>
    <description>For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Sham NBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular Thrombectomy</intervention_name>
    <description>ET is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>NBO group</arm_group_label>
    <other_name>ET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General inclusion criteria&#xD;
&#xD;
          1. It conforms to the indications for endovascular thrombectomy&#xD;
&#xD;
          2. 18≦Age &lt;80 years old.&#xD;
&#xD;
          3. The clinical symptoms and signs are consistent with acute anterior circulation large&#xD;
             vessel occlusion; 10≤NIHSS≤18；&#xD;
&#xD;
          4. (Level of consciousness) NIHSS score 0 or 1;&#xD;
&#xD;
          5. The time from onset to randomization is within 6 hours of onset;&#xD;
&#xD;
          6. The mRS score before stroke is 0-1;&#xD;
&#xD;
          7. Patient and family members sign informed consent. Image inclusion criteria&#xD;
&#xD;
        1. Preoperative CT or MR or DSA angiography found large vessel occlusion (internal carotid&#xD;
        artery or middle cerebral artery M1 segment) that were consistent with symptoms and signs;&#xD;
        2. ASPECT score ≥ 6 points 3. &lt;1/3 MCA area involvement (confirmed by CT or MRI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General exclusion criteria&#xD;
&#xD;
               1. Rapid neurological function improvement, NIHSS score less than 10 points, or&#xD;
                  evidence of vessel recanalization prior to randomization;&#xD;
&#xD;
               2. Seizures at stroke onset;&#xD;
&#xD;
               3. Intracranial hemorrhage;&#xD;
&#xD;
               4. Symptoms suggestive of subarachnoid hemorrhage, even if CT scan was normal;&#xD;
&#xD;
               5. Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant&#xD;
                  therapy with INR &gt; 3.0 or PTT &gt; 3 times normal;&#xD;
&#xD;
               6. Platelet count of less than 100,000 per cubic millimeter;&#xD;
&#xD;
               7. Severe hepatic or renal dysfunction;&#xD;
&#xD;
               8. Severe, sustained hypertension (Systolic Blood Pressure &gt;185 mmHg or Diastolic&#xD;
                  Blood Pressure &gt;110 mmHg)&#xD;
&#xD;
               9. Baseline blood glucose of &lt;50mg/dL (2.78 mmol) or &gt;400mg/dL (22.20 mmol)&#xD;
&#xD;
              10. Active and chronic obstructive pulmonary disease or acute respiratory distress&#xD;
                  syndrome;&#xD;
&#xD;
              11. &gt;3 L/min oxygen required to maintain peripheral arterial oxygen saturation (SaO2)&#xD;
                  95% as per current stroke management guidelines;&#xD;
&#xD;
              12. Medically unstable;&#xD;
&#xD;
              13. Life expectancy&lt;90 days;&#xD;
&#xD;
              14. Patients who could not complete the 90-day follow-up;&#xD;
&#xD;
              15. Evidence of intracranial tumor;&#xD;
&#xD;
              16. Patients with anemia or polycythemia vera or other situations that require urgent&#xD;
                  oxygen inhalation;&#xD;
&#xD;
              17. Patients with upper gastrointestinal bleeding or nausea or vomiting so that they&#xD;
                  cannot cooperate with the mask to inhale oxygen.&#xD;
&#xD;
              18. A history of severe allergies to contrast agents;&#xD;
&#xD;
              19. There are any other conditions that are not suitable for endovascular treatment.&#xD;
&#xD;
              20. mTICI&lt;2b after endovascular treatment.&#xD;
&#xD;
        Image exclusion criteria&#xD;
&#xD;
          1. CTA/MRAshows excessive bending of blood vessels, which may hinder the delivery of the&#xD;
             device;&#xD;
&#xD;
          2. Suspected cerebrovascular inflammation based on medical history and CTA/MRA;&#xD;
&#xD;
          3. Suspected aortic dissection based on medical history and CTA/MRA&#xD;
&#xD;
          4. CTA/MRA confirmed multi-vascular area occlusion (such as bilateral anterior&#xD;
             circulation or anterior/posterior circulation), or bilateral infarction or multi-&#xD;
             regional infarction;&#xD;
&#xD;
          5. CTA/MRAconfirmed moyamoya disease or moyamoya syndrome;&#xD;
&#xD;
          6. CT/MRI confirmed the obvious effect of midline shift&#xD;
&#xD;
          7. CT/MRI confirmed the presence of intracranial tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xunming Ji, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xunming Ji, MD</last_name>
    <phone>01083199439</phone>
    <email>jixm@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weili Li, PhD</last_name>
    <email>liweilibeijing2008@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuan Wu Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xunming ji</last_name>
      <phone>861013120136877</phone>
      <email>jixunming@vip.163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 6, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Normobaric hyperoxia</keyword>
  <keyword>Endovascular treatment</keyword>
  <keyword>Acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

